MU
Michael Ulz Morgan Stanley Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
29
Avg Return
Past Year
Past Year
34%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
66.7%
Neutral
30%
Negative
3.3%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Overweight
Maintained
| $47 |
209%
upside
| 2 | -16% |
0
%
| 3 Mar ‘26 2 days ago |
|
|
|
Equal-Weight
Downgraded
| $7 |
24%
upside
| 2 | +23% |
0
%
| 2 Mar ‘26 3 days ago |
|
|
|
Equal-Weight
Downgraded
| $2 |
301%
upside
| 1 | -68% |
–
| 30 Jan ‘26 1 month ago |
|
|
|
Overweight
Maintained
| $123 |
32%
upside
| 3 | +10% |
0
%
| 30 Jan ‘26 1 month ago |
|
|
|
Equal-Weight
Maintained
| $408 |
25%
upside
| 4 | – |
–
| 30 Jan ‘26 1 month ago |
|
|
|
Equal-Weight
Maintained
| $81 |
24%
upside
| 3 | – |
–
| 7 Jan ‘26 1 month ago |
|
|
|
Overweight
Maintained
| $25 |
182%
upside
| 2 | +148% |
0
%
| 4 Dec ‘25 3 months ago |
|
|
|
Overweight
Maintained
| $94 |
18%
upside
| 4 | +17% |
0
%
| 30 Oct ‘25 4 months ago |
|
|
|
Overweight
Maintained
| $102 |
217%
upside
| 2 | +12% |
0
%
| 23 Oct ‘25 4 months ago |
|
|
|
Outperform
Maintained
| $21 |
130%
upside
| 3 | +24% |
0
%
| 9 Oct ‘25 4 months ago |
|
|
|
Overweight
Maintained
| $25 |
333%
upside
| 2 | +21% |
0
%
| 9 May ‘25 10 months ago |
|
|
|
Overweight
Maintained
| $22 |
541%
upside
| 1 | +147% |
0
%
| 1 Apr ‘25 11 months ago |
|
|
|
Underweight
Maintained
| $7 | – | 1 | -73% |
0
%
| 5 Mar ‘25 1 year ago |
|